TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28741624
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (30 μg ethinyl estradiol/0.15 mg levonorgestrel)
Study: 25947930
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg sublingual melatonin
Study: 25947930
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg sublingual melatonin
Study: 25947930
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg sublingual melatonin
Study: 21038019
Drug: Opt‐FP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opt‐FP 400 µg
Study: 10714758
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin therapy via pen-injector (Novopen II)
Study: 10714758
Drug: Patient-mixed insulin
Normalized name: insulin aspart protamine, human / insulin aspart, human Injectable Suspension [NovoLog Mix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-mixed insulin therapy via conventional syringe
Study: 8234642
Drug: Nightguard vital
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightguard vital bleaching (3-hour exposure with replenishment of test solution hourly)
Study: 8234642
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (glycerin)
Study: 29641362
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch (175 mg) applied to umbilical trocar site
Study: 29641362
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lidocaine patch)
Study: 24261547
Drug: Family-centred music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-centred music therapy (FCMT) for 16 weeks in addition to early intervention programmes
Study: 18721703
Drug: Intracameral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral moxifloxacin 0.5% (250 mug/0.050 mL)
Study: 12855265
Drug: Bio-chemotherapy (bio-CT)
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-chemotherapy (bio-CT)
Study: 10568212
Drug: DHEP lecithin
Normalized name: Lecithin
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP lecithin gel (1.3% DHEP and 2.4% lecithin)
Study: 10568212
Drug: DHEP gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP gel (without lecithin)
Study: 10568212
Drug: DHEP lecithin
Normalized name: Lecithin
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP lecithin gel
Study: 24345165
Drug: D2/D3 dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2/D3 dopamine receptor binding measured using [F-18]fallypride
Study: 17726460
Drug: Mouse TYR
Normalized name: Tyr
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouse TYR DNA vaccine followed by human TYR DNA vaccine (3 injections each, 100, 500, and 1,500 microg DNA/injection, IM every 3 weeks)
Study: 17726460
Drug: Human TYR
Normalized name: IMMUNOGLOBULIN G1 (DE-450-LYSINE), ANTI-(HUMAN TYROSINE KINASE RECEPTOR AXL) (HUMAN-MUS MUSCULUS MONOCLONAL BA301 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL BA301 .KAPPA.-CHAIN, DIMER, THIOETHER WITH N-(((4-((N-(6-(3-MERCAPTO-2,5-DIOXO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human TYR DNA vaccine followed by mouse TYR DNA vaccine (3 injections each, 100, 500, and 1,500 microg DNA/injection, IM every 3 weeks)
Study: 17726460
Drug: Both mouse
Normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both mouse and human TYR DNA vaccines
Study: 15241748
Drug: Home-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physical therapy (PT) program (prehabilitation)
Study: 11756645
Drug: Natural L-glutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural L-glutamine (0.5 g x kg(‐1) x d(‐1))
Study: 25228838
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D group (cholecalciferol 2,000 IU/day + calcium 200 mg/day)
Study: 25228838
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (calcium 200 mg/day)
Study: 11783186
Drug: Neiyi 1+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neiyi 1+ pill (TCM group)
Study: 8724034
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (loviride + lamivudine + zidovudine)
Study: 8724034
Drug: Double combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double combination (loviride + zidovudine)
Study: 30010698
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (RS2) 45 g/d for 12 weeks
Study: 27087153
Drug: 0.005 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005 mg/kg cisatracurium
Study: 27087153
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg cisatracurium
Study: 27087153
Drug: 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg cisatracurium
Study: 17989152
Drug: Aerosolized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized salbutamol (5 mg)
Study: 17989152
Drug: Nebulization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of ipratropium bromide (0.5 mg)
Study: 15309429
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran oil (RBO) with low gamma-oryzanol (0.05 g/d)
Study: 15309429
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran oil (RBO) with high gamma-oryzanol (0.8 g/d)
Study: 7577887
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at 25 ng/min per kg ideal body weight for 90 min after fasting for 12, 36, and 72 hours
Study: 7259326
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion at a dose of 6‐10 ng/kg/min for 72 hours
Study: 31089768
Drug: PZQ +
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ + KTZ (20 mg/kg PZQ + 200 mg ketoconazole)
Study: 31089768
Drug: PZQ alone
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ alone (20 mg/kg)
Study: 26907933
Drug: Bimatoprost Unit
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost Unit Dose Preservative Free (BUDPF)
Study: 26907933
Drug: Latanoprost Unit
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost Unit Dose Preservative Free (LUDPF)
Study: 12499320
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g EPA+DHA (4:0)
Study: 12499320
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g EPA+DHA plus 1 g GLA (4:1)
Study: 12499320
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g GLA (4:2)
Study: 12499320
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g GLA (4:4)
Study: 8869688
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg/day for 3 days)
Study: 8869688
Drug: Prednisolone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (50 mg/day for 3 days)
Study: 1531552
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (detuned ultrasound and detuned short‐wave diathermy)
Study: 31074823
Drug: Ustekinumab therapy
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab therapy for 8 weeks or more
Study: 28658582
Drug: Nitrate supplementation
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplementation (10 mg.kg‐1 body mass of sodium nitrate)
Study: 23388533
Drug: Cycloferon (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloferon (in tablets) administered under standard regimen to frequently ill children (FIC)
Study: 21756323
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg bid (n = 42)
Study: 21756323
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg bid (n = 40)
Study: 21756323
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pioglitazone 30 mg and metformin 1.7 g (n = 39)
Study: 14679315
Drug: Soy-based milk
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-based milk and yoghurt (treatment)
Study: 2899663
Drug: Feverfew (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feverfew (one capsule of dried feverfew leaves a day for four months)
Study: 30575345
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (Group 1)
Study: 27470681
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TA) 1 g loading dose followed by 1 g over 8 hours
Study: 27470681
Drug: Intravenous 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9% normal saline (placebo)
Study: 15125484
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg, p.o.)
Study: 3623744
Drug: Dapsone (DDS)
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone (DDS) 100 mg orally in dogs
Study: 3623744
Drug: Dapsone (DDS)
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone (DDS) 100 mg intravenously in dogs
Study: 3623744
Drug: Dapsone (DDS)
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone (DDS) 50 mg intravenously in healthy volunteers
Study: 3623744
Drug: Dapsone (DDS)
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone (DDS) 50 mg orally in healthy volunteers
Study: 27598379
Drug: Progressive Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive Muscle Relaxation (PMR) technique, performed daily over eight weeks.
Study: 24119823
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of methylphenidate (MPH)
Study: 24119823
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of levodopa (LEV)
Study: 17846935
Drug: No primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No primary antibiotic treatment
Study: 12586130
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg/day and warfarin (INR 2.0-2.5)
Study: 12586130
Drug: Aspirin groups
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin groups combined (n=129)
Study: 28846767
Drug: 50 µg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg/d transdermal 17β‐estradiol (t‐E2)
Study: 28846767
Drug: 0.45 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/d oral conjugated equine estrogens (o‐CEE)
Study: 16197583
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g isomalt daily
Study: 16197583
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g sucrose daily (Control)
Study: 9987085
Drug: Selective endothelin
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective endothelin A (ETA) receptor antagonist BQ-123 (3 mg/hr)
Study: 9987085
Drug: Mixed endothelin-converting
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed endothelin-converting enzyme and neutral endopeptidase inhibitor phosphoramidon (30 nmol/min)
Study: 9987085
Drug: Selective neutral
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective neutral endopeptidase inhibitor thiorphan (30 nmol/min)
Study: 2106274
Drug: Flumazenil 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 0.4 mg
Study: 2106274
Drug: Naloxone 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.05 mg
Study: 29642094
Drug: SPS-MC (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPS-MC (sodium picosulphate/magnesium citrate preparation)
Study: 29642094
Drug: PEG-Asc+B (2-l
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-Asc+B (2-l ascorbic-acid-enriched polyethylene glycol solution plus bisacodyl pretreatment)
Study: 23345581
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of DNA vaccine (Advax) plus 1 dose of recombinant modified vaccinia virus Ankara (MVA) (TBC‐M4)
Study: 23345581
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of TBC‐M4 alone
Study: 21138518
Drug: Epoetin α
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin α (target Hb 9.5 to 11.0 g/dL and 11.5 to 13.0 g/dL)
Study: 12709347
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice a day orally for 7 days)
Study: 12709347
Drug: Chloramphenicol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (500 mg four times a day orally for 14 days)
Study: 9003953
Drug: Serum alpha‐L‐fucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum alpha‐L‐fucosidase activity
Study: 1469466
Drug: BCNU combined
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU combined with vincristine intravenously and procarbazine orally, followed by radiation therapy
Study: 21211380
Drug: Doxazosin 2
Normalized name: doxazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 2 mg once daily for 8 weeks
Study: 21211380
Drug: Doxazosin 2
Normalized name: doxazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 2 mg once daily and Tolterodine 2 mg twice daily for 8 weeks
Study: 16123895
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment (fibre)
Study: 12382386
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine (1 ml)
Study: 12382386
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine (2 ml)
Study: 12382386
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine (1 ml)
Study: 12382386
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine (2 ml)
Study: 7027892
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 12.5 mg, given as 2 tablets o.m.
Study: 7027892
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg o.m. monotherapy
Study: 31735245
Drug: Cognitive-Behavioral Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Group Therapy (CBGT)
Study: 29177434
Drug: AZD4547 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4547 80 mg twice daily, orally, on a 2 weeks on/1 week off schedule of a 21-day cycle
Study: 29177434
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 administered weekly on days 1, 8, and 15 of a 28-day cycle
Study: 25528898
Drug: ESL 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESL 1,200 mg
Study: 25528898
Drug: ESL 800
Normalized name: ESL
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ESL 800 mg
Study: 23450315
Drug: Self-administered Epworth
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered Epworth Sleepiness Scale (ESSs)
Study: 23450315
Drug: Physician-administered Epworth
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician-administered Epworth Sleepiness Scale (ESSp)
Study: 19755930
Drug: Proliferative response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Proliferative response to vaccine antigens
Study: 15188169
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha (9 million units)
Study: 15188169
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon alpha (3 million units)
Study: 11473558
Drug: s-ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-ketamine (0.5 mg kg‐1)
Study: 11367689
Drug: recombinant alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant alpha-2a interferon (1 million units daily for 6 days)
Study: 11367689
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 and Vitamin B1 (conventional dose for 6 days)
Study: 3415884
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 5 ml in sitting position
Study: 3415884
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 5 ml in lateral position
Study: 3415884
Drug: Hyperbaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric solution in sitting position
Study: 3415884
Drug: Hyperbaric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric solution in lateral position
Study: 28873511
Drug: UC‐MSCs (1×10^6
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC‐MSCs (1×10^6 UC‐MSCs/kg, four peripheral intravenous infusions, one infusion per week)
Study: 27029459
Drug: 50-50% N2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-50% N2 O + i.v. remifentanil 0.1 μg/kg/min
Study: 27029459
Drug: remifentanil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 0.1 μg/kg/min
Study: 24941840
Drug: Shenkangling Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenkangling Decoction + Western medicine
Study: 15060505
Drug: Ephedrine plus
Normalized name: EPHEDRINE HYDROCHLORIDE 12.5 mg / GUAIFENESIN 200 mg ORAL TABLET [Red Label Ephedrine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine plus caffeine (25 mg ephedrine, 200 mg caffeine)
Study: 15060505
Drug: Ephedrine alone
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine alone (25 mg)
Study: 15060505
Drug: Caffeine alone
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine alone (200 mg)
Study: 15060505
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg) compared with ephedrine (25 mg)
Study: 9362403
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose conjugated estrogen (1.25 mg)
Study: 9362403
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose conjugated estrogen (10 mg)
Study: 1543426
Drug: Baclofen (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (20mg for one week after titration)
Study: 16982783
Drug: Itraconazole as
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole as NanoCrystal formulation (NCF) 100 mg
Study: 16982783
Drug: Itraconazole as
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole as NanoCrystal formulation (NCF) 300 mg
Study: 16982783
Drug: Itraconazole as
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole as NCF (200 mg)
Study: 16982783
Drug: Itraconazole as
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole as HPBCD solution (200 mg)
Study: 11966762
Drug: Chromium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium (200 microg) and Copper (3.0 mg) supplementation for 12 weeks
Study: 11966762
Drug: Copper (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper (3.0 mg) supplementation for 12 weeks
Study: 11966762
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.394 g lactose)
Study: 10088136
Drug: THA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: THA (25 and 50 mg, orally)
Study: 10150323
Drug: Oral amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amitriptyline
Study: 1704168
Drug: Propafenone 300
Normalized name: propafenone 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 300 mg b.i.d.
Study: 1704168
Drug: Quinidine slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine slow-release 800 mg b.i.d.
Study: 17067504
Drug: Non-fractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fractionated heparin (nFH) at 5-7 U/kg/hour
Study: 17067504
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of epoprostenol and nFH at 2.5 U/kg/hour
Study: 11281369
Drug: Hydrocortisone 15
Normalized name: hydrocortisone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 15 mg per day
Study: 11281369
Drug: Hydrocortisone 20
Normalized name: hydrocortisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 20 mg per day
Study: 11281369
Drug: Hydrocortisone 30
Normalized name: hydrocortisone 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 30 mg per day